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a b s t r a c t
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the key enzyme in choles-
terol biosynthesis. Their extensive use in treatment and prevention of cardiovascular diseases placed
statins among the best selling drugs. Construction of Saccharomyces cerevisiae cell factory for the pro-
duction of high concentrations of natural statins will require establishment of a non-destructive self-
resistance mechanism to overcome the undesirable growth inhibition effects of statins. To establish
active export of statins from yeast, and thereby detoxiﬁcation, we integrated a putative efﬂux pump-
encoding gene mlcE from the mevastatin-producing Penicillium citrinum into the S. cerevisiae genome.
The resulting strain showed increased resistance to both natural statins (mevastatin and lovastatin) and
semi-synthetic statin (simvastatin) when compared to the wild type strain. Expression of RFP-tagged
mlcE showed that MlcE is localized to the yeast plasma and vacuolar membranes. We provide a possible
engineering strategy for improvement of future yeast based production of natural and semi-synthetic
statins.
& 2015 International Metabolic Engineering Society. Published by Elsevier B.V. International Metabolic
Engineering Society. All rights reserved.
1. Introduction
Statins are used as cholesterol-lowering drugs in treatment and
prevention of coronary heart diseases, and their extensive world-
wide usage placed them among the best selling pharmaceuticals in
the past decade (GBI Research, 2013). The application of statins in
medicine is based on their ability to inhibit the catalytic action of
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR).
HMGCR constitutes the rate-limiting enzyme in the mevalonate
pathway, which is responsible for the production of sterols, such
as cholesterol in animal cells, and ergosterol in fungi (Maury et al.,
2005). Natural statins are synthesized as secondary metabolites by
ﬁlamentous fungi; mevastatin (Fig. 1A) by Penicillium citrinum
(Endo et al., 1976), and lovastatin (Fig. 1B) by Aspergillus terreus
(Alberts et al., 1980) and Monascus ruber (Endo, 1979). Industrial
scale production of natural statins and their semi-synthetic deri-
vatives (e.g. simvastatin and pravastatin) is based on fermentation
of statin-producing ﬁlamentous fungi (Manzoni and Rollini, 2002;
Singh and Pandey, 2013). Production limitations associated with
the unique physiology and morphology of these natural producers
can be overcome by heterologous expression of the biosynthetic
pathway in a fast-growing host, such as Saccharomyces cerevisiae.
It will, however be crucial to establish a nondestructive resistance
mechanism in yeast to overcome the undesirable growth inhibi-
tion effects of statins. One such mechanism could be active export
of statins. Export systems have previously proved to be efﬁcient in
increasing the tolerance of microorganisms to the produced
compounds, either relying on native efﬂux pumps, as it has been
shown for the production of several antibiotics (Malla et al., 2010;
Ullán et al., 2002; Xu et al., 2012), or via heterologous pumps as
shown in Escherichia coli in connection with biofuel synthesis
(Dunlop et al., 2011).
Secondary metabolite gene clusters, in addition to the catalytic
enzymes, often encode proteins for secretion of the produced
bioactive compounds and thereby also a self-resistance mechan-
ism (reviewed in Martín et al., 2005). This is also likely the case for
the known statin clusters, where putative efﬂux pump encoding
genes are present; mlcE in the mevastatin cluster (Fig. 1A) (Abe
et al., 2002), and lovI or mokI in the lovastatin cluster of A. terreus
(Kennedy et al., 1999) or M. ruber (Chen et al., 2008), respectively
(Fig. 1B). Given the industrial importance of the microbial statin-
producing cell factories it is surprising that only limited evidence
concerning the function of the putative efﬂux pumps in the statin
gene clusters has been provided so far. Hutchinson et al. found
that A. terreus lovI mutants did not produce lovastatin or any of its
known precursors, and that heterologous expression of lovI in
Aspergillus nidulans, a lovastatin sensitive species, did not result in
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increased lovastatin resistance (unpublished result in Hutchinson
et al., 2000). These ﬁndings did not clarify the function of the
putative efﬂux pumps in the statin-producing fungi. Nevertheless,
understanding the statin transport mechanism could open up an
alternative avenue to classical metabolic engineering strategies
aimed at increased productivity of the natural statin-producing
strains (Barrios-González and Miranda, 2010). Moreover, genes
encoding for the statin transporters can represent a pool of can-
didates for co-expression in a heterologous host, such as S. cere-
visiae, thus open up a possibility to establish the necessary self-
resistance mechanism for the production of statins in yeast.
In this study, we investigate the function of the putative efﬂux
pump MlcE from the P. citrinum mevastatin gene cluster and ex-
plore its potential to confer statin resistance in S. cerevisiae.
2. Materials and methods
2.1. Bioinformatics
Protein sequences were obtained from UniProtKB (Consortium,
2013). Protein topology prediction was carried out using TOPCONS
web server (Bernsel et al., 2009). Prediction of subcellular locali-
zation was performed with CELLO v.2.5 (Yu et al., 2006). For
phylogenetic tree construction the protein sequences were aligned
with the multiple sequence alignment tool Multiple sequence
Alignment using Fast Fourier Transform (MAFFT) (Katoh et al.,
2009) available at the European Bioinformatics Institute (EMBL-
EBI) (McWilliam et al., 2013). See Supplementary Table S1 for the
list of protein sequences used for the tree construction. The
phylogenetic tree was generated with the ClustalW2 alignment
extension (Larkin et al., 2007) at EMBL-EBI using the Neighbor
joining clustering method, with the following setting: distance
correction on, exclude gaps on. FigTree software, version 1.4 was
used for displaying the tree.
2.2. Construction of plasmids and strains
A yeast codon-optimized version of the mlcE gene, de novo
synthetized by Genscript, was PCR ampliﬁed from the plasmid
pEN669 with primers mlcE-F and mlcE-R. The S. cerevisiae TEF1
promoter was ampliﬁed from the plasmid pSP-G2 (Partow et al.,
2010) using primers TEF1-d and PGK1-s. The ampliﬁed fragments
were cloned into the pX-3 targeting vector (Mikkelsen et al., 2012)
via the USER cloning technique (Nour-Eldin et al., 2006) resulting
in plasmid pX3-TEF1-mlcE-CYC1. The subcellular localization of
MlcE was determined by tagging it C-terminally with monomeric
red ﬂuorescent protein (RFP). For that plasmid pX3-TEF1-mlcE-
RFP-CYC1 and a control plasmid pX3-TEF1-RFP-CYC1 were con-
structed as follows: the coding sequence of mlcE lacking the stop
codon was ampliﬁed using the primer pair mlcE-F and mlcE-RFP-
R, and a yeast codon-optimized RFP was ampliﬁed from plasmid
pWJ1350 (Lisby et al., 2003) using the primers RFP_Rþ and either
RFP-F (for tagging mlcE) or RFP_Fþ (for the control plasmid). All
fragments were ampliﬁed by PCR using a USER cloning compatible
PfuX7 polymerase (Nørholm, 2010). Escherichia coli DH5α
(Woodcock et al., 1989) was used as host for USER cloning ex-
periments and for the propagation of the constructed plasmids.
The inserts of the resulting plasmids were veriﬁed by sequencing
(StarSEQ). The constructed plasmids were digested with the NotI
Fig. 1. Natural statins and their biosynthetic gene cluster: (A) Mevastatin and its gene cluster from P. citrinum. (B) Lovastatin and its gene clusters from M. ruber (mok genes)
and A. terreus (lov genes). The putative efﬂux pump genes are shown in gray.
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enzyme (New England Biolabs), and the obtained linear fragments
were used for yeast transformation using the lithium acetate/sin-
gle-stranded carrier DNA/polyethylene glycol transformation
method (Gietz and Schiestl, 2007). The linear gene targeting cas-
settes were integrated into the X-3 locus of the reference yeast
strain, S. cerevisiae CEN.PK 113-11C as described by Mikkelsen et al.
(2012). The URA3markers in the constructed strains were removed
by direct repeat recombination using 5-FOA (Melford) counter
selection. Correct integration of substrates was veriﬁed by diag-
nostic colony PCR with one primer annealing outside of the in-
tegration site in the yeast genome (X-3-up-out-sq), and one sub-
strate speciﬁc primer (C1_TADH1_F). Oligonucleotides, plasmids
and strains used in this study are listed in Table 1.
2.3. Media
The E. coli transformants were selected on lysogeny broth (LB)
medium containing 100 mg/mL of ampicillin. Yeast strains were
cultivated in standard liquid or solid yeast peptone dextrose
medium (YPD), synthetic complete medium (SC), or synthetic
medium (SM). SC medium was prepared according to Sherman
et al. (1986), with the minor modiﬁcation that the L-leucine con-
centration was doubled to 60 mg/L. Yeast transformants were se-
lected on SC medium lacking uracil. Removal of the URA3 marker,
via direct repeat recombination, was achieved by growing the
strain on SC medium containing 5-ﬂuororotic acid (5-FOA;
740 mg/L, Sigma-Aldrich) and uracil (30 mg/L).
For susceptibility experiments strains were grown aerobically
either on YPD plates or in SM, supplemented with compounds as
described below. SM was prepared according to Verduyn et al.
(1992), but concentrations of (NH4)2SO4 and KH2PO4 were
modiﬁed to 7.5 g/L and 14.4 g/L, respectively. SM was supple-
mented with uracil (150 mg/L; Sigma-Aldrich) and L-Histidine
(125 mg/L; Sigma-Aldrich) (Pronk, 2002). The pH was adjusted to
6.5 with a 2 M NaOH solution. Glucose was added as carbon source
to a ﬁnal concentration of 20 g/L. The compounds used in the
susceptibility experiments were prepared as follows: stock solu-
tions of vanillin (320 mM), mycophenolic acid (MPA, 50 mM) and
atorvastatin (10 mM) were prepared by dissolving the compounds
in 99% ethanol. Mevastatin, lovastatin, and simvastatin stock so-
lutions (50 mM) were prepared as described previously (Morimoto
et al., 2013). Brieﬂy, the solid compounds were dissolved in 1 mL of
99% ethanol, preheated to 50 °C, alkalinized with 0.5 mL of 0.6 M
NaOH and incubated at 50 °C for 2 h. The pH of the solutions was
then adjusted to 7.2 by adding 0.4 M HCl. The ﬁnal volume of the
solutions was adjusted to 2 mL with water, resulting in stock so-
lutions of 50 mM. All stock solutions were ﬁlter-sterilized and
stored at 20 °C. Mevastatin and atorvastatin were purchased
from Toronto Research Chemicals, lovastatin from Tokyo Chemical
Industry, MPA and vanillin from Sigma-Aldrich, and simvastatin
from Ark Pharm.
2.4. Fluorescent microscopy
For ﬂuorescent microscopy the mlcE-RFP- and RFP-expressing
strains (ARX1 and ARX2, respectively) were cultured in liquid SC
medium at 30 °C with 150 rpm agitation overnight and analyzed
by ﬂuorescence and visible light microscopy using a Nikon Eclipse
E1000 microscope equipped with an oil-immersed objective at
100 magniﬁcation. The images were captured with QImaging
Retiga Exi digital camera using Image Pro Plus 5.1 software. The
brightness of images to be compared was adjusted pairwise using
Table 1
Oligonucleotides, plasmids and strains used in this study. U¼2-deoxyuridine.
Primer name Primer sequence (50– 30) Use
mlcE-F AGCGATACGUAAAAATGAGTGAACCATTACC Ampliﬁcation of mlcE from plasmid pEN669
mlcE-R CACGCGAUTTATGCATCAGTCTCAG
TEF1-d ACGTATCGCUGTGAGTCGTATTACGGATCCTTG Ampliﬁcation of promoter sequence from plasmid pSP-
G2PGK1-s CGTGCGAUGCCGCTTGTTTTATATTTGTTG
RFP_Fþ ATGGCCTCCUCCGAGGACGTCATCAAGGAG Ampliﬁcation of RFP from plasmid pWJ1350
RFP_Rþ CACGCGAUCTAGGCGCCGGTGGAGTGGCGG
mlcE-RFP-R AGGAGGCCAUTGCATCAGTCTCAGGGAC Ampliﬁcation of mlcE from plasmid pX3-TEF1-mlcE-
CYC1
RFP-F AGCGATACGUAAAAATGGCCTCCTCCGAG Ampliﬁcation of RFP from plasmid pX3-TEF1-mlcE-RFP-
CYC1
X-3-up-out-sq TGACGAATCGTTAGGCACAG Strain conﬁrmation via colony PCR
C1_TADH1_F CTTGAGTAACTCTTTCCTGTA
Plasmid name Description Reference or source
pEN669 Template for amplifying mlcE (S. cerevisiae codon optimized) From Evolva Holding SA
pWJ1350 Template for amplifying RFP Lisby et al. (2003)
pSP-G2 Template for amplifying TEF1 Partow et al. (2010)
pX3 USER cloning vector equipped with the CYC1 terminator designed to target site
3 on chromosome X.
Mikkelsen et al. (2012)
pX3-TEF1-mlcE-CYC1 Plasmid carrying a gene-targeting cassette for expressing mlcE in yeast. This study
pX3-TEF1-RFP-CYC1 Plasmid carrying a gene-targeting cassette for expressing RFP-tagged mlcE in yeast. This study
pX3-TEF1-mlcE-RFP-
CYC1
Plasmid carrying a gene-targeting cassette for expressing RFP in yeast. This study
Strain name Genotype Reference or source
Escherichia coli
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mKþ) phoA
supE44 λ– thi-1 gyrA96 relA1




MATα MAL2-8C SUC2 his3Δ ura3-52 Dr. Petter Kötter, Institut für Mikrobiologie, der Johan
Wolfgang Goethe-Universität, Frankfurt am Main,
Germany
ARX1 MATα MAL2-8C SUC2 his3Δ ura3-52X3::PTEF1mlcE-RFP-Tcyc1 This study
ARX2 MATα MAL2-8C SUC2 his3Δ ura3-52X3::PTEF1-RFP-Tcyc1 This study
ARX3 MATα MAL2-8C SUC2 his3Δ ura3-52X3::PTEF1-mlcE-Tcyc1 This study
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Adobe Photoshop CS6.
2.5. Susceptibility experiments
For susceptibility assays on solid media tenfold dilution series
of S. cerevisiae WT and ARX3 strains (Table 1), starting with an
OD600 of 0.02 were prepared from overnight cultures in SC med-
ium (30 °C/150 rpm). 4.5 mL of each dilution were plated on a set of
YPD agar plates containing different cytotoxic compounds. The
plates were incubated at 30 °C for 3 days, after which the growth
of the yeast strains was recorded by photography.
For susceptibility assay in liquid medium, strains were grown
aerobically in SM, containing different concentrations of lovasta-
tin. Yeast optical density measurements were performed in 48
wells plates in a plate reader (BioTek's Synergy™ Mx Microplate
Reader) at 30 °C with fast shaking intensity setting (19 Hz speed,
linear shake, which translates into 1140 rpm according to the
BioTek's instructions) in 400 mL of SM. Cells were harvested from
overnight shake ﬂask cultures (30 °C/150 rpm) in late exponential
phase and diluted to an OD600 of 0.1 in SM medium with 0.7, 1.2 or
2.0 mM of activated lovastatin or an equal volume of control so-
lution (99% ethanol treated as described above—preparation of the
compounds for the susceptibility experiments). Triplicate OD600
measurements were taken every 5 min for 24 h.
3. Results and discussion
3.1. Topology prediction and phylogenetic clustering of MlcE
MlcE, a putative efﬂux pump from the P. citrinum mevastatin
biosynthetic gene cluster shows signiﬁcant sequence similarity to
drug resistance proteins of the major facilitator superfamily (MFS)
(Marger and Saier, 1993). MFS transporters are characterized by
using the proton gradient across the plasma membrane as an
energy source for the translocation they mediate (Pao et al., 1998).
The drug resistance protein subfamily of MFS transporters is
further divided into two families, depending on the number of
transmembrane spanning regions (TMS) the proteins consist of:
12-TMS family and 14-TMS family (Paulsen and Skurray, 1993;
Paulsen et al., 1996), also termed as Drug:Hþ antiporter 12 TMS
(DHA12) family, and 14 TMS (DHA14) family, respectively (Pao
et al., 1998). The performed phylogenetic analysis showed that
MlcE, as well as LovI and MokI (Fig. 2), clustered with known
members of 14-TMS family of drug resistance proteins, such as the
cercosporin facilitator protein (CFP) from Cercospora kikuchii
(Callahan et al., 1999) and HC-toxin efﬂux pump (ToxA) from Co-
chliobolus carbonum (Pitkin et al., 1996) (further proteins are listed
in Supplementary Table S1). This classiﬁcation is supported by the
performed topology prediction, which showed that MlcE com-
prises of 14 TMS (data not shown), indicating that it is indeed a
member of 14-TMS family. We next performed an in silico pre-
diction of MlcE's subcellular localization, using CELLO v.2.5 to see
where in eukaryotic cells the protein would be localized. The
prediction suggests that it is most likely localized at the plasma
membrane (score¼4.942 and a combined reliability score of 0.997
for the ﬁve used prediction methods). Collectively, this proposes
that MlcE is likely localized in the plasma membrane and functions
as a statin efﬂux pump driven by the proton gradient found across
the plasma membrane.
3.2. Subcellular localization of MlcE
To experimentally determine the subcellular localization of
MlcE in S. cerevisiae we tagged MlcE with the red ﬂuorescent
protein (RFP) at its carboxylic terminus and expressed it as a single
copy gene from the yeast genome (Fig. 3A). Fluorescent micro-
scopy of the resulting strain, ARX1, revealed a ring-like distribu-
tion of the ﬂuorescent protein at the periphery of the cells and
inside the vacuole (Fig. 3B), indicating that the RFP-tagged MlcE
was localized to the plasma and vacuolar membranes. In contrast,
when RFP was expressed alone it was found to have a uniform
cytoplasmic distribution in the control cells ARX2. This subcellular
localization of MlcE in S. cerevisiae supports the hypothesis that
Fig. 2. Phylogenetic clustering of putative statin efﬂux pumps (MlcE, MokI and LovI) with major facilitator superfamily (MFS) transporters involved in the efﬂux of toxic
compounds, belonging to the subfamily of proteins with 14 transmembrane domains (14-TMS family). Proteins used to construct the phylogenetic tree are listed in Sup-
plementary Table S1, where information about the source organism and the substrate of each protein is provided.
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MlcE is a transmembrane protein, which is localized to the plasma
membrane.
3.3. Investigation of the potential of MlcE to confer the resistance to
statins in S. cerevisiae
We next tested if the localization of MlcE to the yeast plasma
membrane would enable it to export statins from yeast, and
thereby increase the yeast's resistance to statins. For that, mlcE
was expressed from a deﬁned genomic locus in S. cerevisiae as a
single copy gene under the control of the strong constitutive
promoter TEF1 (Fig. 4A). The resulting strain ARX3 was tested for
its susceptibility to mevastatin, MlcE's predicted natural substrate,
by serial dilution plating on YPD agar plates supplemented with
the active form of mevastatin. The mlcE-expressing strain showed
an increased resistance to mevastatin compared to the reference
strain (Fig. 4B).
To determine if MlcE would be able to excrete other structurally
related compounds, we tested the effects of lovastatin and sim-
vastatin. Again, the mlcE-expressing strain displays an increased
resistance compared to the reference strain, and the putative
pump was able to protect the cells against both the natural statin
lovastatin and its semi-synthetic derivative simvastatin (Fig. 4B).
This shows that MlcE is able to accept not only its native substrate
but also structurally related natural compounds, and even com-
pounds it has not encountered during evolution, when expressed
in yeast. To determine whether MlcE should be considered as a
general pleiotropic efﬂux pump, or a dedicated statin pump, we
tested the susceptibility of the ARX3 strain to other toxic com-
pounds. This analysis showed that MlcE was not able to protect
yeast against the lethal effects of the synthetic statin, atorvastatin
or the effects of the natural compounds vanillin and mycophenolic
acid (MPA) (Fig. 4B). These results suggest that MlcE is not a multi-
drug resistance efﬂux pump. The speciﬁcity of MlcE and its pre-
sence in the mevastatin biosynthetic gene cluster suggest that it
has likely evolved as a statin efﬂux pump; however, testing in the
endogenous species is still required to conﬁrm this.
3.4. MlcE and a future S. cerevisiae based statin cell factory
Statins are currently commercially produced by fermentation of
natural statin-producing species of ﬁlamentous fungi. The highest
titers reported for these systems have been achieved by sub-
merged cultivation, reaching levels up to 950 mg/L (2.35 mM) of
lovastatin (Jia et al., 2010) and 1200 mg/L (3.07 mM) of mevastatin
(Choi et al., 2004), respectively. For future heterologous production
of statins to be competitive, these titers will likely have to be
matched and preferably exceeded. For the last decade several
groups have been working on establishing S. cerevisiae based statin
cell factories, and in 2013, Xu et al. succeed in producing dihy-
dromonacolin L acid (0.11 mM), the ﬁrst stable intermediate in the
lovastatin pathway (Xu et al., 2013). However, no one has yet re-
ported whether S. cerevisiae will be able to cope with the required
product levels. To test this, we cultured the reference wild type
strain (WT) in liquid synthetic medium supplemented with in-
creasing concentrations of activated lovastatin in a micro-fer-
mentation setup. The analysis revealed that the IC50 value for ex-
tracellularly added lovastatin is approx. 1 mM (less than half of the
required concentration) in the wild type and that even low con-
centrations of lovastatin greatly reduced the aerobic maximum
speciﬁc growth rate and ﬁnal optical density (Table 2).
These results show the necessity of establishing a non-de-
structive self-resistance mechanism in a future yeast statin cell
factory to allow for titers similar to those reported for statin-
producing ﬁlamentous fungi. For this, MlcE constitutes a potential
tool for tackling the described self-intoxication problem. To in-
vestigate if it would also provide protection from statins in liquid
cultures, the MlcE expressing strain (ARX3) was tested as de-
scribed above for the reference wild type strain (Table 2). The
analysis showed that while the growth of S. cerevisiae wild type
strain was almost completely inhibited at lovastatin concentra-
tions similar to those achieved by fermentation of A. terreus,
growth of the ARX3 strain was only slightly affected by the same
high concentration of lovastatin. The liquid culture experiment
also allowed for determination of the strains growth efﬁciencies
(Table 2), which revealed that expression of mlcE did have a cost
(9% reduction), but that this cost did not change as function of the
statin concentration, within the tested concentration range.
Direct proof of the effects of implementing the MlcE based
resistance in a S. cerevisiae statin cell factory is currently not
possible as only part of the biosynthetic pathway at this time has
been established in yeast (Xu et al., 2013). However, im-
plementation could likely have additional beneﬁts such as in-
creasing titers by reducing feedback inhibition of the pathway
enzymes caused by high intracellular concentrations of statins and
furthermore reduce product puriﬁcation costs.
4. Conclusions
We provide evidence that mlcE from the P. citrinum mevastatin
biosynthetic gene cluster encodes a transmembrane protein that
localizes to the plasma and vacuolar membranes in S. cerevisiae.
Moreover, MlcE signiﬁcantly increases yeast resistance to both,
natural and semi-synthetic statins, likely by exporting the com-
pounds from the cells. This resistance mechanism has a potential
to improve future yeast based production of natural and semi-
Fig. 3. Subcellular localization of MlcE in S. cerevisiae: (A) strain construction
summary and (B) ﬂuorescent microscopy of the constructed strains (see Section 2
for experimental details).
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synthetic statins.
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